New anti-VEGF may improve vision in some patients initially treated with other agents

MIAMI — Some patients currently being treated with bevacizumab or ranibizumab may experience an improvement in visual acuity if their treatment regimen is switched to aflibercept, a speaker said here. Presenting four patient cases, Jason S. Slakter, MD, said Eylea (aflibercept, Regeneron) may create a “marked improvement” in the eye’s anatomy.

Full Story →